Pediatrix Medical Group (NYSE:MD) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of Pediatrix Medical Group (NYSE:MD - Free Report) from a buy rating to a hold rating in a report issued on Thursday morning.

MD has been the subject of several other reports. Mizuho boosted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, November 19th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research report on Monday, November 4th. Macquarie started coverage on shares of Pediatrix Medical Group in a report on Monday. They issued an "outperform" rating and a $18.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group raised their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $16.42.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock traded up $0.24 during midday trading on Thursday, reaching $14.25. 920,638 shares of the company's stock were exchanged, compared to its average volume of 852,212. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock's 50-day simple moving average is $14.11 and its 200 day simple moving average is $10.90. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -4.66, a P/E/G ratio of 2.00 and a beta of 1.57. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analysts' expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business's revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 earnings per share. On average, analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the firm's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company's stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors have recently added to or reduced their stakes in the company. Aristeia Capital L.L.C. purchased a new position in shares of Pediatrix Medical Group in the second quarter worth about $687,000. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the period. Principal Financial Group Inc. grew its position in shares of Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company's stock valued at $5,953,000 after purchasing an additional 63,581 shares in the last quarter. Weiss Asset Management LP raised its stake in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after purchasing an additional 306,143 shares during the period. Finally, RBF Capital LLC bought a new stake in shares of Pediatrix Medical Group during the third quarter valued at about $1,695,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.